First-in-human phase I study of EMB-02, a bispecific antibody targeting PD-1 and LAG-3 in patients with advanced solid tumors
Daphne Day(Monash Medical Centre), Jun Guo(Peking University)
Cited by 7
Related Papers
Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma
|BMC Cancer|2014|54
RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinoma
|Cell Death and Disease|2019|50